BURDEN OF ILLNESS: DIRECT AND INDIRECT ECONOMIC COSTS OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UNITED STATES
Author(s)
Tiffanie Tran, PharmD1, Alexis Sohn, PharmD, MPH, MS1, Kimberly M Deininger, PhD, MPH1, Greg Kricorian, MD1, Joyce Qian, PhD, MPH2, Fiona Herr, PhD2;
1Amgen Inc., Thousand Oaks, CA, USA, 2Kyowa Kirin, Inc., Princeton, NJ, USA
1Amgen Inc., Thousand Oaks, CA, USA, 2Kyowa Kirin, Inc., Princeton, NJ, USA
OBJECTIVES: To describe economic burden of moderate-to-severe atopic dermatitis (M2SAD) in the US.
METHODS: This retrospective observational study used administrative claims data from 01Jan2017-31Dec2023 to describe patient characteristics, all-cause and AD-related healthcare resource utilization (HCRU), healthcare costs (HCC), AD-related treatment utilization, and oral corticosteroids (OCS) dosage over a fixed 24-month follow-up among patients >12yo with M2SAD. Absenteeism and associated indirect costs were assessed for adults (18-64yo). Eligible patients were identified based on the first systemic treatment or topical ruxolitinib claim within 30 days of the first of ≥2 separate AD diagnosis claims from 01Jan2018-31Dec2021.
RESULTS: Among all 25,269 patients (mean 42.5yo; 61.3% female; mean Charlson Comorbidity Index [CCI], 0.7), majority (61.8%) initiated systemic corticosteroids (SCS), 34.2% advanced therapy (AT; biologics, JAKis or topical ruxolitinib), and 4.0% systemic immunosuppressants (SIS) at index. During follow up, SCS remained the most common treatment for all patients (80.7%), followed by topical corticosteroids (71.5%), AT (37.0%), and SIS (6.9%). 89.3% of patients had AD-related outpatient office visits, most commonly with dermatologists (49.7%), primary-care (30.8%), and allergist/immunologists (15.1%).
Among the adolescents subgroup (N=3,346; mean 14.6yo; 57.2% female; mean CCI, 0.4) 36.9% initiated AT, 2.5% SIS, and 60.5% SCS at index. During follow up, SCS remained most used (73.6%), followed by topical corticosteroids (68.5%), AT (39.8%), and SIS (4.1%). 92.8% of patients had AD-related outpatient visits, most commonly with dermatologists (47.5%) and allergist/immunologists (24.8%).
Mean total all-cause HCC was $27,255 per-patient-per-year for adults (18-64yo; N=19,177) and $21,200 for adolescents, with 44.6% attributable to AD management (adults) vs 60.4% (adolescents). Mean annual productivity losses (N=413) attributable to absenteeism per employee was $4,760.
CONCLUSIONS: AD management contributed substantially to total HCC. Despite lower overall spending, AD-related costs and specialist use was higher in adolescents vs. adults. Findings highlight unmet needs and support continued improvement in M2SAD management to lessen economic burden.
METHODS: This retrospective observational study used administrative claims data from 01Jan2017-31Dec2023 to describe patient characteristics, all-cause and AD-related healthcare resource utilization (HCRU), healthcare costs (HCC), AD-related treatment utilization, and oral corticosteroids (OCS) dosage over a fixed 24-month follow-up among patients >12yo with M2SAD. Absenteeism and associated indirect costs were assessed for adults (18-64yo). Eligible patients were identified based on the first systemic treatment or topical ruxolitinib claim within 30 days of the first of ≥2 separate AD diagnosis claims from 01Jan2018-31Dec2021.
RESULTS: Among all 25,269 patients (mean 42.5yo; 61.3% female; mean Charlson Comorbidity Index [CCI], 0.7), majority (61.8%) initiated systemic corticosteroids (SCS), 34.2% advanced therapy (AT; biologics, JAKis or topical ruxolitinib), and 4.0% systemic immunosuppressants (SIS) at index. During follow up, SCS remained the most common treatment for all patients (80.7%), followed by topical corticosteroids (71.5%), AT (37.0%), and SIS (6.9%). 89.3% of patients had AD-related outpatient office visits, most commonly with dermatologists (49.7%), primary-care (30.8%), and allergist/immunologists (15.1%).
Among the adolescents subgroup (N=3,346; mean 14.6yo; 57.2% female; mean CCI, 0.4) 36.9% initiated AT, 2.5% SIS, and 60.5% SCS at index. During follow up, SCS remained most used (73.6%), followed by topical corticosteroids (68.5%), AT (39.8%), and SIS (4.1%). 92.8% of patients had AD-related outpatient visits, most commonly with dermatologists (47.5%) and allergist/immunologists (24.8%).
Mean total all-cause HCC was $27,255 per-patient-per-year for adults (18-64yo; N=19,177) and $21,200 for adolescents, with 44.6% attributable to AD management (adults) vs 60.4% (adolescents). Mean annual productivity losses (N=413) attributable to absenteeism per employee was $4,760.
CONCLUSIONS: AD management contributed substantially to total HCC. Despite lower overall spending, AD-related costs and specialist use was higher in adolescents vs. adults. Findings highlight unmet needs and support continued improvement in M2SAD management to lessen economic burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE403
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)